Abdul Mannan: A Normal Factor Level Can Still Miss the Story
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“A normal factor level can still miss the story.
That is the false reassurance trap in haemophilia carriers.
The lab result matters. Of course it does. But it should never be used as a permission slip to ignore bleeding symptoms.
Here’s what I want every trainee to remember:
- FVIII and FIX levels are risk clues
- Bleeding history is a clinical signal
- Heavy periods, nosebleeds, oral bleeding, bruising, procedure bleeding, and joint pain all matter
- A structured BAT or HMB screen can change the conversation
- Symptomatic carriers need a documented plan and review
- Haemophilia Carrier Post 1 of 8
One number rarely explains the whole patient.
The better question is not, ‘Is the factor level normal?’
The better question is, ‘Does the bleeding phenotype fit the life this patient is living?’
That small change can stop years of reassurance without action.
What phrase do you use in clinic to move from ‘normal result’ to ‘proper bleeding assessment’?”
More posts from Dr Abdul Mannan on Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery